ReviewJournal of lipid and atherosclerosis2026

Cardiovascular Risk Reduction With Tirzepatide, a Dual GIP/GLP-1 Agonist, in Patients With Type 2 Diabetes Mellitus.

Sakiko Terui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.